Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10‐year pharmacovigilance analysis

Eculizumab is the first and only medication approved for paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) treatment. However, eculizumab safety based on long‐term pharmacovigilance is unknown. This analysis summarises safety data collected from spontaneous a...

Descripción completa

Detalles Bibliográficos
Autores principales: Socié, Gérard, Caby‐Tosi, Marie‐Pierre, Marantz, Jing L., Cole, Alexander, Bedrosian, Camille L., Gasteyger, Christoph, Mujeebuddin, Arshad, Hillmen, Peter, Vande Walle, Johan, Haller, Hermann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Red Cells and Iron
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594003/
https://www.ncbi.nlm.nih.gov/pubmed/30768680
http://dx.doi.org/10.1111/bjh.15790

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594003/
https://www.ncbi.nlm.nih.gov/pubmed/30768680
http://dx.doi.org/10.1111/bjh.15790

Ejemplares similares